HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 is produced primarily in specialized intestinal cells called L-cells, located throughout the small intestine and colon, and secondarily in pancreatic alpha cells. Recent research shows L-cells account for approximately 60–70% of total GLP-1 secretion in response to nutrient intake.

Knowing where GLP-1 is produced becomes clinically relevant when considering how your genetic makeup may influence your natural GLP-1 signaling and response. PlexusDx emphasizes precision-wellness approaches that connect anatomical understanding with individual genetic context to support more informed healthcare conversations.

The Intestinal L-Cells: Your Body's Primary GLP-1 Source

L-cells are neuroendocrine cells distributed throughout the small intestine and colon, with the highest concentration in the ileum and colon. These cells release GLP-1 in response to nutrient detection, particularly glucose and lipids, triggering postprandial insulin secretion and satiety signals.

The intestinal epithelium contains approximately 100 million L-cells producing GLP-1 daily. This distributed production allows rapid, localized hormone release that affects glucose metabolism, gastric motility, and appetite regulation within minutes of nutrient exposure.

Anatomical and Functional GLP-1 Production Comparison

Understanding where GLP-1 originates helps explain how the hormone influences metabolism and why genetic variations in GLP-1 receptor signaling pathways may affect individual responses to treatment approaches.

Production Site Primary Function Response Time Clinical Significance
Intestinal L-cells (ileum/colon) Nutrient sensing, insulin secretion, satiety Minutes post-meal Largest GLP-1 source; dietary-responsive
Pancreatic alpha cells Glucose-dependent insulin suppression Minutes during hyperglycemia Secondary source; tightly regulated
Brainstem (nucleus tractus solitarius) Appetite and satiety signaling Central processing delays Neuronal integration, not primary source
Enteric neurons Local mucosal coordination Immediate local effects Supports intestinal motility and secretion

GLP-1R Genetic Variants and Individual Production Capacity

The GLP1R rs6923761 single nucleotide polymorphism is associated with natural variations in GLP-1 receptor signaling efficiency. Some individuals carry genetic variants that may influence how effectively their cells respond to endogenous GLP-1, potentially affecting baseline metabolic regulation.

These genetic predispositions do not determine medication response alone but may provide context for provider discussions about treatment approach. Understanding your genetic profile alongside anatomy helps inform more personalized clinical conversations about which interventions might align with your biological baseline.

When to Consider Biomarker and Genetic Assessment with Your Provider

Before starting any GLP-1-based treatment, discuss with your healthcare provider whether understanding your genetic predispositions in peptide pathways could support your care plan. Biomarker evaluation—including fasting glucose, HbA1c, and lipid panels—establishes your metabolic baseline alongside genetic context.

The Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R pathways. This information should be interpreted with a qualified healthcare provider and is intended to complement, not replace, standard medical evaluation and provider guidance on treatment selection.

How PlexusDx Supports a More Personalized Approach

PlexusDx emphasizes that while GLP-1 is produced anatomically in specific tissues, individual response to GLP-1-based approaches may vary based on genetic predispositions in receptor signaling pathways. Our genetic testing framework may help provide context for provider conversations about personalized treatment planning.

The Precision Peptide Genetic Test examines key variants including GLP1R rs6923761 and GIPR rs1800437, which relate to receptor sensitivity and nutrient-response capacity. These results reveal predispositions in peptide genetic pathways and should be interpreted with a qualified healthcare provider—not as predictors of exact medication response.

Understanding both where GLP-1 is naturally produced and your individual genetic profile can support a more comprehensive discussion with your healthcare provider about whether compounded semaglutide, compounded tirzepatide, or other precision approaches align with your specific health context.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Exactly where in the body is GLP-1 produced?

GLP-1 is primarily produced in intestinal L-cells throughout the small intestine and colon, and secondarily in pancreatic alpha cells. The intestine accounts for approximately 60–70% of total GLP-1 secretion in response to nutrient intake.

How much GLP-1 does the body naturally produce daily?

The body's approximately 100 million L-cells produce GLP-1 continuously in response to meals, with peak levels occurring 15–30 minutes after eating. Precise daily production varies based on diet, metabolic state, and individual physiology.

What does the Precision Peptide Genetic Test reveal about my GLP-1 production capacity?

The test examines GLP1R rs6923761 and related variants to reveal predispositions in your GLP-1 receptor signaling pathways. Results should be interpreted with a provider—they indicate genetic context, not your exact GLP-1 production level or medication response.

Can genetics affect how my body responds to GLP-1 treatment?

Genetic variants in GLP-1 receptor and related pathways may influence individual responses to treatment, though genetics alone do not determine outcomes. A provider can discuss your genetic predispositions alongside clinical assessment to support personalized treatment conversations.

How does understanding GLP-1 production sites help me choose a treatment approach?

Understanding anatomy plus your genetic predispositions allows for more informed discussions with your provider about whether compounded semaglutide, tirzepatide, or other options may align with your specific metabolic and genetic context. This supports precision-wellness decision-making.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.